SCHEMBL13217

SCHEMBL13217

CCn1ncc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.61
CYP1A2 P05177 1/20 0.56
KMO O15229 1/20 0.54
DAO P14920 1/20 0.49
POLB P06746 4/20 0.48
HSD17B10 Q99714 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TSHR P16473 2/20 0.48
ADRA2A P08913 1/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SLC9A1 P19634 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC6A2 P23975 1/20 0.43
P2RX7 Q99572 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487730 0.85 RECQL (0.46) RECQLCYP1A2KMODAOPOLB
SCHEMBL5565705 0.84 CYP1A2 (0.62) RECQLCYP1A2KMODAOPOLB
SCHEMBL29487638 0.84 CYP1A2 (0.62) RECQLCYP1A2KMODAOPOLB
SCHEMBL1326630 0.81 CYP1A2 (0.58) RECQLCYP1A2KMODAOPOLB
SCHEMBL7331551 0.81 RECQL (0.69) RECQLCYP1A2KMODAOPOLB
SCHEMBL7332016 0.80 RECQL (0.53) RECQLCYP1A2KMODAOPOLB
SCHEMBL861732 0.80 CYP1A2 (0.57) RECQLCYP1A2KMODAOPOLB
SCHEMBL9934408 0.79 RECQL (0.61) RECQLCYP1A2KMODAOPOLB
SCHEMBL29520910 0.79 RECQL (0.61) RECQLCYP1A2KMODAOPOLB
SCHEMBL29520779 0.79 RECQL (0.61) RECQLCYP1A2KMODAOPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024193328-A1 INDAZOLE SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 汤亚杰 2024-09-26 WO claimed
US-20230052747-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS TES PHARMA S.R.L. (IT) 2023-02-16 US claimed
EP-1255797-B2 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES OMG ELECTRONIC CHEMICALS INC (US) 2016-10-12 EP claimed
EP-1255797-B1 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES OMG ELECTRONIC CHEMICALS INC (US) 2012-06-13 EP claimed
EP-2419551-A2 ELECTROLYTE AND SURFACE-ACTIVE ADDITIVES FOR THE GALVANIC DEPOSITION OF SMOOTH, DENSE ALUMINUM LAYERS FROM IONIC LIQUIDS BASF SE (DE) 2012-02-22 EP claimed
US-20120006688-A1 ELECTROLYTE AND SURFACE-ACTIVE ADDITIVES FOR THE ELECTROCHEMICAL DEPOSITION OF SMOOTH, DENSE ALUMINUM LAYERS FROM IONIC LIQUIDS BASF SE (DE) 2012-01-12 US claimed
JP-4754752-B2 2011-08-24 JP claimed
WO-2010106072-A2 ELECTROLYTE AND SURFACE-ACTIVE ADDITIVES FOR THE GALVANIC DEPOSITION OF SMOOTH, DENSE ALUMINUM LAYERS FROM IONIC LIQUIDS BASF SE (DE) 2010-09-23 WO claimed
EP-1255797-A4 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES ELECTROCHEMICALS INC (US) 2009-01-14 EP claimed
CN-100340632-C Method for roughening copper surfaces for bonding to substrates ELECTROCHEMICALS INC (US) 2007-10-03 CN claimed
CN-1451031-A Method for roughening copper surfaces for bonding to substrates ELECTROCHEMICALS INC (US) 2003-10-22 CN claimed
JP-2003519286-A 2003-06-17 JP claimed
EP-1255797-A1 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES ELECTROCHEMICALS INC. (US) 2002-11-13 EP claimed
WO-2001049805-A1 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES ELECTROCHEMICALS INC. (US) 2001-07-12 WO claimed
US-5543517-A VIRICIDES THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-08-06 US claimed
US-20260055062-A1 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC 2026-02-26 US disclosed
US-12492171-B2 Heterocyclic inhibitors of MCT4 Vettore, LLC (US) 2025-12-09 US disclosed
EP-1255797-A1 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES ELECTROCHEMICALS INC. (US) 2002-11-13 EP disclosed
US-20020084441-A1 Method for roughening copper surfaces for bonding to substrates MACDERMID, INCORPORATED 2002-07-04 US disclosed
WO-2001049805-A1 METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES ELECTROCHEMICALS INC. (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492171-B2 Heterocyclic inhibitors of MCT4 SLC16A3, SLC16A1, MCTS1 RECQL 2496/4885CYP1A2 2974/4885KMO 1510/4885
US-20230052747-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS RAD51, BRCA1, FANCI RECQL 29/4885CYP1A2 1815/4885KMO 3566/4885
US-20260055062-A1 HETEROCYCLIC INHIBITORS OF MCT4 SLC16A1, SLC16A3, SLC16A7 RECQL 3317/4885CYP1A2 2037/4885KMO 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.